SEC Stock Data Quick Answer Adaptimmune Therapeutics PLC reported R&D Expense of $149.06 million for fiscal year 2024. Adaptimmune Therapeutics PLC R&D Expense — Annual History Fiscal Year R&D Expense YoY Change 2024 $149.06M +17.8% 2023 $126.51M -1.0% 2022 $127.73M +15.0% 2021 $111.09M +21.3% 2020 $91.57M -6.1% 2019 $97.50M -0.8% 2018 $98.27M +12.5% 2017 $87.39M +37.0% 2016 $63.79M … Read more
Quick Answer Adaptimmune Therapeutics PLC reported Stockholders Equity of $11.85 million for fiscal year 2024. Adaptimmune Therapeutics PLC Stockholders Equity — Annual History Fiscal Year Stockholders Equity YoY Change 2024 $11.85M -70.0% 2023 $39.51M -51.7% 2022 $81.88M -60.2% 2021 $205.96M -39.6% 2020 $341.23M +176.0% 2019 $123.64M -49.9% 2018 $246.88M +21.6% 2017 $202.98M +22.2% 2016 $166.14M … Read more
Quick Answer Adaptimmune Therapeutics PLC reported Long-Term Debt of $50.24 million for fiscal year 2024. Adaptimmune Therapeutics PLC Long-Term Debt — Annual History Fiscal Year Long-Term Debt YoY Change 2024 $50.24M — Quarterly Long-Term Debt Quarter Ending Long-Term Debt YoY QoQ June 30, 2025 $25.68M +2.9% +1.0% March 31, 2025 $25.41M — -49.4% December 31, … Read more
Quick Answer Adaptimmune Therapeutics PLC reported Cash and Equivalents of $91.14 million for fiscal year 2024. Adaptimmune Therapeutics PLC Cash and Equivalents — Annual History Fiscal Year Cash and Equivalents YoY Change 2024 $91.14M -36.7% 2023 $143.99M +33.3% 2022 $108.03M -28.0% 2021 $149.95M +163.6% 2020 $56.88M +12.8% 2019 $50.41M -26.3% 2018 $68.38M -18.6% 2017 $84.04M … Read more
Quick Answer Adaptimmune Therapeutics PLC reported Total Assets of $245.96 million for fiscal year 2024. Adaptimmune Therapeutics PLC Total Assets — Annual History Fiscal Year Total Assets YoY Change 2024 $245.96M -13.0% 2023 $282.62M -14.1% 2022 $328.92M -30.0% 2021 $469.55M +4.1% 2020 $451.14M +148.5% 2019 $181.54M -34.4% 2018 $276.74M -1.6% 2017 $281.15M +19.9% 2016 $234.51M … Read more
Quick Answer Adaptimmune Therapeutics PLC reported Diluted EPS of $0.05 per share (loss) for fiscal year 2024. Adaptimmune Therapeutics PLC Diluted EPS — Annual History Fiscal Year Diluted EPS YoY Change 2024 -$0.05 +44.4% 2023 -$0.09 +47.1% 2022 -$0.17 +0.0% 2021 -$0.17 -13.3% 2020 -$0.15 +31.8% 2019 -$0.22 — Quarterly Diluted EPS Quarter Ending Diluted … Read more
Quick Answer Adaptimmune Therapeutics PLC reported Net Income of -$70.81 million for fiscal year 2024. Adaptimmune Therapeutics PLC Net Income — Annual History Fiscal Year Net Income YoY Change 2024 -$70.81M +37.8% 2023 -$113.87M +31.2% 2022 -$165.46M -4.7% 2021 -$158.09M -21.5% 2020 -$130.09M +5.2% 2019 -$137.16M -43.6% 2018 -$95.51M -36.2% 2017 -$70.14M +2.0% 2016 -$71.58M … Read more
Quick Answer Adaptimmune Therapeutics PLC reported Revenue (ASC 606) of $178.03 million for fiscal year 2024. Adaptimmune Therapeutics PLC Revenue (ASC 606) — Annual History Fiscal Year Revenue (ASC 606) YoY Change 2024 $178.03M +195.3% 2023 $60.28M +122.0% 2022 $27.15M +341.5% 2021 $6.15M +55.4% 2020 $3.96M +252.8% 2019 $1.12M -98.1% 2018 $59.51M +57.3% 2017 $37.83M … Read more
Quick Answer Adaptimmune Therapeutics PLC reported Total Revenue of $178.03 million for fiscal year 2024. Adaptimmune Therapeutics PLC Total Revenue — Annual History Fiscal Year Total Revenue YoY Change 2024 $178.03M +195.3% 2023 $60.28M +122.0% 2022 $27.15M +341.5% 2021 $6.15M +55.4% 2020 $3.96M +252.8% 2019 $1.12M -98.1% 2018 $59.51M +57.3% 2017 $37.83M +166.5% 2016 $14.20M … Read more
Quick Answer Adaptimmune Therapeutics PLC reported Total Revenue of $178.03 million for fiscal year 2024. Adaptimmune Therapeutics PLC — Key Financials by Year Metric 2024 2023 2022 2021 2020 2019 Total Revenue $178.03M+195.3% $60.28M+122.0% $27.15M+341.5% $6.15M+55.4% $3.96M+252.8% $1.12M-98.1% Revenue (ASC 606) $178.03M+195.3% $60.28M+122.0% $27.15M+341.5% $6.15M+55.4% $3.96M+252.8% $1.12M-98.1% Net Income -$70.81M+37.8% -$113.87M+31.2% -$165.46M-4.7% -$158.09M-21.5% -$130.09M+5.2% -$137.16M-43.6% … Read more